Novartis keeps firms waiting for results of global panel review

Premium content

This article is only available to Premium subscribers of The Lawyer. Premium subscribers benefit from accessing all of our award-winning online content including interviews, commentary, analysis and in-depth research.

View our subscription options

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

View our subscription options

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here 

Latest Briefings

Responsibilities of the members of the board of directors due to public debts

By Gülenay Kavcar In the light of the decision of the Constitutional Court regarding the application of EROL KESGİN dated 2015/11192 and dated 30.05.2019, the members of the Board of Directors who are not represented have the responsibility of the liability of the Board of Directors.     I. BRIEF SUMMARY OF THE CONSEQUENT EVENT The provincial […]

Do I need to get planning permission for the changes I want to make to home?

By Martín Casas If you’re thinking about  doing works on your house or garden, one of the things you will be thinking about (or should be thinking about!) is if you need to obtain planning permission. In most cases you will need planning permission, but there are a few occasions where you don’t. Probably the most […]

The impact of economic substance rules on family offices in the Channel Islands

By Richard Laignel, Alice Bricogne The economic substance legislation that came into force in Guernsey and Jersey in January 2019 requires companies that are tax resident in either island, and that conduct one or more of the defined activities, to demonstrate that they meet threshold levels of physical substance in their respective jurisdictions. How do the rules […]

Standard collaterals in commercial lease agreements on polish market

Under a lease agreement, a landlord commits to hand over a thing for a tenant’s use for a fixed or non-fixed term and the tenant commits to pay the landlord the agreed rent. When the lease ends, the tenant is obliged to return the thing in a non-deteriorated condition; however, is not liable for normal […]

The employer’s obligation on labour safety and hygiene in mongolia

By Bolormaa Volodya Mongolia is one of the wealthiest countries in the world of mineral resources and has developed its own independent mining industry since 1990. The country has joined the implementation of European and international technical, environmental and occupational safety and health standards in the mining sector to improve its competitiveness in the public […]

Recommended

Novartis

Macfarlanes leads as Novartis moves HQ to London

Macfarlanes is advising on Novartis’s HQ move to White City, as the Swiss drugs giant sets its sights on joining a cluster of life sciences companies in West London. Novartis’s 600 HQ staff will relocate from Frimley in Surrey to the WestWorks building on the White City Place campus within the UK’s “golden triangle” bioscience hub […]

/h/y/s/novartis_317.jpg

Hogan Lovells wins the top role for Novartis in $9bn pharma deal

Hogan Lovells and Cravath Swaine & Moore have won the top roles on Novartis’ $9bn purchase of Chicago-based gene therapy company AveXis. The deal, in which the Swiss pharmaceutical giant is offering $218 per share for AveXis, is being led by Hogan Lovells Washington DC-based corporate transactions partner Joseph Gilligan who is advising Novartis. He is working alongside New […]

Blood

A&O, Osborne Clarke and Proskauer Rose advise on $1.7bn Novartis deal

Allen & Overy (A&O), Osborne Clarke (OC) and Proskauer Rose have taken mandates advising on the $1.7bn (£1bn) sale of Swiss pharmaceutical giant Novartis’ transfusion diagnostics unit to Spanish plasma therapies company Grifols. Barcelona-headquartered Grifols will acquire the transfusion diagnostics unit of Novartis for US$1,675bn (£1,04bn). The assets include medical products and technology, as well […]

/h/y/s/novartis_317.jpg
1

Novartis unveils panel designed to build ‘long-term partnerships’

Novartis has announced the results of its first panel review since the company’s $40bn takeover of Alcon, with three magic circle firms – Allen & Overy, Freshfields Bruckhaus Deringer and Linklaters – securing spots on the global roster along with two US firms. Pharma company Novartis’s new panel, called the legal preferred firm programme, is […]

Recruit legal talent

Get your role in front of over 300,000 legal professionals when you advertise with The Lawyer. Our team of experts provide bespoke solutions to help solve all your recruitment challenges.

Find out more

Register now to The Lawyer to access our latest news stories, read selected briefings from key firms and gain essential careers insight to help you make the most of your current and future roles.

Contact Us: if you have any questions regarding your subscription, call us on +44 (0)20 7292 3716 or email us at customerservices@thelawyer.com

View our subscription options

Having problems?

Contact us on +44 (0)20 7292 3716 | email: customerservices@thelawyer.com

If you are looking for our Jobs site, please click here